St. Jude, Boston Scientific ICD Sales Growth Flat-Lines In Q3 – Rebound In ’07?
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical is more than halfway through a planned 500-rep expansion of its U.S. implantable cardioverter defibrillator sales force as part of its broader effort to reignite ICD sales growth
You may also be interested in...
Remotely Monitored ICDs Propel Medtronic’s 6% Market Share Gain
Expanding availability and increasing market acceptance of Medtronic's Virtuoso ICD and Concerto cardiac resynchronization therapy product drove a 14% sequential quarterly advance in defibrillator sales, allowing the company to capture market share
Remotely Monitored ICDs Propel Medtronic’s 6% Market Share Gain
Expanding availability and increasing market acceptance of Medtronic's Virtuoso ICD and Concerto cardiac resynchronization therapy product drove a 14% sequential quarterly advance in defibrillator sales, allowing the company to capture market share
Lemonade From Lemons: Boston Scientific CEO On The Changes At Guidant
Boston Scientific's makeover of Guidant is "not rocket science," but "adds up to a major cultural shift" at the recently acquired subsidiary, said Boston Scientific CEO Jim Tobin